Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19324663 | MARINE ORGANISM INFUSED EFFERVESCENT TABLET FOR PRODUCING ENHANCED SUSPENSIONS | September 2025 | January 2026 | Allow | 4 | 0 | 1 | Yes | No |
| 18871962 | 1,4-BIS-(2-HYDROXY-BENZYL)-1,4,7-TRIAZACYCLONONANE DERIVATIVES AND SIMILAR COMPOUNDS AS LIGANDS IN IRON(III) COMPLEXES FOR USE AS MRI CONTRAST AGENTS | December 2024 | June 2025 | Allow | 6 | 0 | 1 | No | No |
| 18915867 | HYDROXYAPATITE-ENCLOSED ZINC PHOSPHATE NANOCOMPOSITE | October 2024 | December 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18902113 | POLYMER NANOPARTICLE COMPOSITIONS FOR IN VIVO EXPRESSION OF POLYPEPTIDES | September 2024 | July 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18669670 | NEAR-INFRARED (NIR) ABSORBING PHOTOSENSITIZERS | May 2024 | January 2026 | Allow | 20 | 1 | 1 | Yes | No |
| 18643088 | STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF | April 2024 | February 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 18640787 | CHITOSAN-HYBRIDIZED ZINC PHOSPHATE/HYDROXYAPATITE NANOSTRUCTURE-BASED DRUG DELIVERY SYSTEM | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18637431 | NANOPARTICLES WITH NON-COVALENTLY BOUND TARGETING MOIETIES FOR USE IN A THERAPEUTIC METHOD AND FOR NON-MEDICAL USE | April 2024 | August 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18625544 | Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use Thereof | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18617245 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF | March 2024 | November 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18595720 | GEL MATERIAL FOR OPHTHALMIC TREATMENT USE | March 2024 | June 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18588605 | COMPOSITIONS AND METHODS OF USE THEREOF | February 2024 | September 2025 | Allow | 19 | 2 | 0 | Yes | No |
| 18392458 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18392939 | REJUVENATION OF CAR T CELL | December 2023 | December 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18530764 | NOVEL, HEAVY VITAMIN B12 DERIVATIVES | December 2023 | February 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18529587 | VIRUCIDAL NANOPARTICLES AND USE THEREOF AGAINST INFLUENZA VIRUS | December 2023 | May 2025 | Allow | 18 | 1 | 1 | No | No |
| 18524929 | RADIOPAQUE NANOPARTICLES FOR MEDICAL IMAGING | November 2023 | March 2026 | Allow | 27 | 4 | 0 | Yes | No |
| 18518499 | APPLICATION OF PHENYL GLUCURONIDE IN PREPARING DRUG FOR PRE-WARNING OF CANCER VIA INDUCED VOLATOLOMICS | November 2023 | August 2024 | Allow | 9 | 1 | 0 | No | No |
| 18516167 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | November 2023 | May 2025 | Allow | 17 | 0 | 1 | Yes | No |
| 18503465 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | November 2023 | February 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18498744 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | October 2023 | October 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18368695 | ABSORBABLE SUTURE CONTAINING HYALURONIC ACID AND MANUFACTURING METHOD THEREFOR | September 2023 | May 2025 | Abandon | 20 | 3 | 0 | Yes | No |
| 18233135 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | August 2023 | August 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18351291 | CONJUGATES ENHANCING TOTAL CELLULAR ACCUMULATION | July 2023 | April 2025 | Allow | 21 | 3 | 0 | No | No |
| 18338832 | METHOD FOR CONJUGATING ANTIBODY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE | June 2023 | February 2024 | Allow | 8 | 0 | 0 | No | No |
| 18022800 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | June 2023 | February 2026 | Allow | 35 | 0 | 0 | No | No |
| 18202377 | DRESSINGS COMPRISING PLATELET LYSATE | May 2023 | November 2025 | Allow | 30 | 2 | 1 | No | No |
| 18038851 | PEPTIDE RECEPTOR RADIONUCLIDE THERAPY | May 2023 | January 2026 | Allow | 32 | 0 | 0 | No | No |
| 18317747 | RADIOPAQUE POLYMERS | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18142409 | TOPICAL GLYCOPYRROLATE FORMULATIONS | May 2023 | July 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18142017 | Contact Lenses And Other Eye-Contacting Matrices Carrying Mitochondrially-Targeted Antioxidants | May 2023 | April 2025 | Abandon | 23 | 2 | 0 | Yes | No |
| 18187709 | METHOD FOR PREPARING CYCLODEXTRIN METAL ORGANIC FRAMEWORK (CD-MOF) STABLE IN AQUEOUS PHASE | March 2023 | May 2023 | Allow | 2 | 0 | 0 | No | No |
| 18101636 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | January 2023 | May 2024 | Allow | 16 | 1 | 0 | No | No |
| 18152430 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | January 2023 | March 2026 | Abandon | 38 | 4 | 0 | Yes | No |
| 18063613 | SURFACE CONJUGATION TO POLY(AMINE-CO-ESTER) NANOPARTICLES FOR TARGETING TO CELLS AND TISSUES | December 2022 | May 2025 | Abandon | 29 | 4 | 0 | Yes | No |
| 17996420 | STERICALLY SHIELDED HEPTAMETHINE CYANINE DYES | October 2022 | July 2025 | Allow | 33 | 0 | 0 | No | No |
| 18045596 | NOVEL, HEAVY VITAMIN B12 DERIVATIVES | October 2022 | September 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17962297 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | October 2022 | December 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17939528 | POLY (BETA-AMINO ESTERS) AND USES THEREOF | September 2022 | January 2023 | Allow | 5 | 0 | 0 | No | No |
| 17885974 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | August 2022 | August 2023 | Allow | 12 | 1 | 1 | No | No |
| 17879441 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | August 2022 | March 2024 | Allow | 19 | 2 | 0 | No | Yes |
| 17879430 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | August 2022 | March 2024 | Allow | 19 | 2 | 0 | No | Yes |
| 17794807 | NOVEL GADOLINIUM-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND MRI CONTRAST AGENT CONTAINING SAME | July 2022 | May 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17810591 | NOVEL BLOCK COPOLYMER AND MICELLE COMPOSITIONS AND METHODS OF USE THEREOF | July 2022 | May 2024 | Allow | 22 | 3 | 0 | Yes | No |
| 17790079 | MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY | June 2022 | September 2025 | Allow | 39 | 0 | 0 | Yes | No |
| 17851454 | LANTHANIDE COMPLEX FORMULATIONS | June 2022 | April 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17838638 | METHOD FOR REMOVING ACETALDEHYDE | June 2022 | January 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 17784215 | CGRP ANTIGONISTS USEFUL AS TRACER COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | June 2022 | April 2025 | Allow | 34 | 0 | 0 | No | No |
| 17834773 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | June 2022 | May 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17774529 | CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF | May 2022 | July 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17773282 | DIRECT FLUORESCENT GLYCAN LABELING | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17755429 | SODIUM-DEPENDENT GLUCOSE TRANSPORTER 2 AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR PRE-MALIGNANT LESIONS | April 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17725237 | DRUG COMBINATION TREATMENTS USING BONE-TARGETING THERAPEUTICS FOR BONE AND BONE-RELATED DISEASE | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17722491 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | April 2022 | August 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17701021 | SOLVENT FREE GADOLINIUM CONTRAST AGENTS | March 2022 | July 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17699457 | CROSSLINKABLE POLYMER COMPOSITIONS | March 2022 | May 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17697369 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | March 2022 | July 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17640259 | MANGANESE CHELATE ISOMERS | March 2022 | March 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17638755 | PHOTOSENSITIZER-CONJUGATED ANTIMICROBIAL CELLULOSE NANOCRYSTALS AND METHODS OF SYNTHESIZING AND USING SAME | February 2022 | March 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17674512 | NOOTROPIC FULLERENES AND USE | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17671128 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | February 2022 | July 2023 | Allow | 17 | 1 | 0 | No | No |
| 17587595 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | January 2022 | September 2025 | Allow | 43 | 4 | 0 | No | No |
| 17585118 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | January 2022 | February 2026 | Allow | 49 | 6 | 1 | Yes | No |
| 17581465 | FULLERENE GABA DOPA AND METHODS | January 2022 | April 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17579967 | C60 GLUTATHIONE DOPA AND METHODS | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17535168 | BIOCOMPATIBLE MAGNETIC MATERIALS | November 2021 | December 2024 | Allow | 37 | 2 | 1 | Yes | Yes |
| 17604590 | NANO-ANTIBIOTICS BASED ON SINGLE-CHAIN DEXTRAN NANOPARTICLES | October 2021 | August 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17501608 | ATHEROSCLEROSIS IMAGING AGENTS AND METHODS OF USING THE SAME | October 2021 | November 2025 | Abandon | 49 | 2 | 0 | No | Yes |
| 17594193 | LOCALIZATION OF PAYLOAD DELIVERY SYSTEMS TO TUMOR SITES VIA BEACON CELL TARGETING | October 2021 | October 2024 | Allow | 36 | 2 | 1 | No | No |
| 17476852 | PYRIMIDINE NUCLEOSIDE COMPOUNDS FOR FLUORESCENCE IMAGING AND SPECTROSCOPY | September 2021 | February 2025 | Allow | 41 | 0 | 0 | No | No |
| 17440129 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | September 2021 | November 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17437678 | DOSAGE FORM COMPRISING A POLYMERIC MATRIX | September 2021 | November 2022 | Allow | 15 | 2 | 0 | Yes | No |
| 17470643 | COMPLEX | September 2021 | April 2024 | Allow | 31 | 2 | 0 | No | No |
| 17437579 | HYDROGELS AND METHODS OF USING THE SAME | September 2021 | January 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17434450 | COMPOSITION AND COMPOSITE | August 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17434445 | POLARIZATION SOURCE FOR DYNAMIC NUCLEAR POLARIZATION, COMPOSITION, COMPOSITION FOR DYNAMIC NUCLEAR POLARIZATION, METHOD FOR HYPERPOLARIZATION, HYPERPOLARIZED SUBSTANCE AND NMR MEASUREMENT METHOD | August 2021 | June 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17433252 | In Vitro Assays as Indicator of Local Tolerance | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17408972 | NANOPARTICLES FOR CANCER DETECTION | August 2021 | April 2024 | Abandon | 32 | 2 | 0 | Yes | No |
| 17431396 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS WITH IMPROVED TISSUE SPECIFICITY | August 2021 | January 2026 | Abandon | 53 | 2 | 1 | Yes | No |
| 17393837 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | August 2021 | November 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17385735 | RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETO | July 2021 | August 2023 | Allow | 24 | 2 | 0 | No | No |
| 17425857 | DELIVERY OF MACROMOLECULES INTO THE CENTRAL NERVOUS SYSTEM VIA THE BLOODSTREAM | July 2021 | December 2025 | Abandon | 52 | 2 | 1 | No | Yes |
| 17368574 | PHOTODYNAMIC THERAPY COMPOSITION | July 2021 | September 2025 | Allow | 50 | 5 | 0 | Yes | Yes |
| 17357345 | COMPOSITE MEDICAL TEXTILE WITH NON-RESORBABLE FIBERS AND BIORESORBABLE HYALURONAN-BASED FIBERS | June 2021 | March 2024 | Abandon | 32 | 5 | 0 | Yes | No |
| 17416180 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | June 2021 | May 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17415649 | DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF | June 2021 | May 2025 | Allow | 46 | 1 | 1 | No | No |
| 17414508 | PHARMACEUTICAL COMPOSITIONS COMPRISING GD-COMPLEXES AND POLYARYLENE ADDITIVES | June 2021 | December 2024 | Allow | 42 | 5 | 0 | No | No |
| 17348157 | THERMOGELLING SUPRAMOLECULAR SPONGE AS SELF-HEALING AND BIOCOMPATIBLE HYDROGEL | June 2021 | June 2024 | Allow | 36 | 2 | 0 | Yes | Yes |
| 17339843 | TOPICAL GLYCOPYRROLATE FORMULATIONS | June 2021 | May 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17329891 | RADIOPAQUE POLYMERS | May 2021 | December 2023 | Allow | 31 | 2 | 0 | No | Yes |
| 17309345 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | May 2021 | May 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17295647 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF | May 2021 | January 2024 | Allow | 32 | 2 | 0 | Yes | No |
| 17313424 | Hemocompatibility Modifiers For Cross-Linked Polymeric Material | May 2021 | December 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17290605 | CROSS-LINKED SUPRAMOLECULAR NANOPARTICLES FOR CONTROLLED RELEASE OF ANTIFUNGAL DRUGS AND STEROIDS - A NEW THERAPEUTIC APPROACH FOR ONYCHOMYCOSIS AND KELOID | April 2021 | April 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17238473 | Crosslinked Gels Comprising Polyalkyleneimines, And Their Uses As Medical Devices | April 2021 | July 2023 | Allow | 27 | 2 | 0 | No | No |
| 17286123 | CHEMILUMINESCENT AND FLUORESCENT NANOPARTICLE FOR OPTICAL IMAGING OF CANCER | April 2021 | December 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17226028 | VACCINES AND VACCINE COMPONENTS FOR INHIBITION OF MICROBIAL CELLS | April 2021 | November 2023 | Allow | 31 | 0 | 0 | No | No |
| 17283412 | BIO-INSPIRED DEGRADABLE TOUGH ADHESIVES FOR DIVERSE WET SURFACES | April 2021 | December 2025 | Abandon | 56 | 5 | 1 | Yes | No |
| 17214118 | COATED BODY AND COATING COMPOSITION | March 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17280760 | DEGRADABLE HYALURONIC ACID HYDROGELS | March 2021 | December 2025 | Allow | 56 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROGERS, JAMES WILLIAM.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ROGERS, JAMES WILLIAM works in Art Unit 1618 and has examined 1,048 patent applications in our dataset. With an allowance rate of 45.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner ROGERS, JAMES WILLIAM's allowance rate of 45.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ROGERS, JAMES WILLIAM receive 2.55 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ROGERS, JAMES WILLIAM is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +17.4% benefit to allowance rate for applications examined by ROGERS, JAMES WILLIAM. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 15.3% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.2% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 74.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 65.9% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 58.0% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.9% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.